Global Marketplace
for
Genomic Discovery
Global Marketplace for
Genomic Discovery
Heloderma suspectum
United States and Mexico
Exendin-4 → GLP-1 agonists
Of a billion or so species on Earth, humans have full genomic sequences for fewer than 100,000 of them. Within the genomic data of the remaining 99.999% of life lies the future of drug discovery, food security, materials science, and biotech. And like every precious resource, this data is unevenly distributed across (and within) geographic boundaries.
Fairfield enables sovereign providers of this data to benefit from contributing it to global science, while providing researchers with clear contractual terms for the commercial use of validated data. To unblock the bottleneck, we provide validated data and legal frameworks, ensuring that everything that's discovered can benefit everyone, everywhere.
The Problem
A global data discovery crisis
The world's biological data is vast, urgent, and almost entirely inaccessible.
<0.01%
of species on Earth have full genomic sequences available
Of a billion or so species, we have meaningful genomic data for a vanishingly small fraction. The potential locked in the rest is enormous, urgent, and untapped.
95%+
of genomic data requests are rejected or ignored
Countries, institutions, communities, and companies hold vast collections of data, but refuse to make them available. They’ve been burned. Biological data is extracted, value gets exploited, and providers see nothing in return.
0
trusted commercial mechanisms to make the world’s biological data discoverable to everyone
The Nagoya Protocol established policy frameworks. But no commercial infrastructure exists to give providers the legal protections and revenue they need to participate, and to give users binding assurance that their data is valid and legal.
The Solution
A trusted marketplace for genomic data
Fairfield creates the commercial layer where policy alone has failed. Providers retain sovereignty. Users get legal access. Everyone benefits from what the data produces.
Sovereignty preserved
Fairfield operates a federated model, in which genomic data remains on provider infrastructure, under provider control. Data never leaves the provider, until a contract is signed.
Revenue on commercialization
Providers gain financial benefits whenever their data contributes to commercial outcomes, from drug discovery and beyond, to AI model training. For validated non-commercial research, access is free.
Legally clear
Everything in Fairfield’s catalog of data is governed by clear contractual terms built up from Nagoya Access and Benefit Sharing frameworks.
Annotation, harmonization, and metadata
Fairfield validates and enriches provider data at no cost to users or providers. Genomic metadata makes provider data discoverable by users, and returns immediate value to providers themselves.
Advancing global research
Academic and validated researchers get access free; the commercial model is integral to funding science in non-commercial context. The world’s data benefits the world’s scientists.
What Drives Us
Why this matters
01
Invaluable, incalculable potential
From novel therapeutics to climate-resilient crops to advances in biotech we can't yet imagine, the breakthroughs dormant in unsequenced biology will reshape entire industries.
02
Economic value for providers
The commercial value of this data belongs, in part, to the sovereign providers who contribute it. Fairfield ensures providers benefit, whenever their genomic data creates commercial outcomes.
03
Scientific value for everyone
The scientific value produced by this vast reservoir of new knowledge can't be carried across borders, just to end up in someone's moat. Fairfield is independent infrastructure to benefit everyone, everywhere, forever.
Who We Serve
Two sides of a single marketplace
For Data Providers
Nations, institutions, and collections
Your genomic data is sovereign. Fairfield gives you a safe, legal, and commercially rewarding way to make it discoverable to the world, without giving up control.
For Researchers & Industry
Pharma, biotech, ag tech, AI, and academia
Access genomic data that has been locked away for decades. Validated, annotated, and governed by clear legal terms. No more rejected requests. No more legal risk.
Fairfield Bio is in active conversations with national governments, research institutions,
and global health organizations across six continents.
Whether you're generating unique genomic data, or need access to that novel data for R&D,
we'd love to figure out how to unblock the bottleneck together.